DemeRx ‘forging ahead’ with Atai Life Sciences to dose patients in Phase 1 ibogaine clinical trial
DemeRx IB, Inc. CEO Deborah Mash joined Proactive New York to discuss the group’s joint venture with Atai Life Sciences (NASDAQ:ATAI), focused on developing ibogaine to treat opioid use disorder. Mash says the group has recently dosed its first patient with an oral form of......
12 October, 2021